Boehringer Ingelheim

This study tested the safety of a new medicine called BI 770371 in 28 adults with compensated cirrhosis caused by MASH (a type of fatty liver disease). Participants received either the drug or a placebo as an intravenous infusion every 3 weeks for 12 weeks. The main goal was to s…

This study tested an experimental drug called BI 907828 (Brigimadlin) in 99 adults with advanced cancers of the bile duct, pancreas, lung, or bladder that had not responded to other treatments. Participants took the drug as a tablet once every 3 weeks. The goal was to see if the …

This study tested a new medicine called survodutide (BI 456906) in 755 adults with overweight or obesity and type 2 diabetes. Participants received weekly injections of either the medicine or a placebo for about 76 weeks, along with diet and exercise advice. The main goal was to …

This study tested an experimental drug called BI 655064 in 121 people with active lupus nephritis, a kidney disease caused by lupus. The goal was to see if adding this drug to standard treatment could improve kidney function after one year. Participants received one of three dose…

This study tested a new medicine called survodutide in 274 Japanese adults with obesity. Participants received weekly injections of either the drug or a placebo for about 1.5 years, along with diet and exercise advice. The goal was to see if survodutide helps people lose more wei…

This study tested a single intravenous dose of spesolimab in 53 adults with generalized pustular psoriasis (GPP) experiencing a moderate-to-severe flare. The main goal was to see if the drug could clear visible pustules within one week compared to a placebo. Results help determin…

This study tested a new oral drug, brigimadlin, against standard chemotherapy (doxorubicin) in 400 adults with advanced dedifferentiated liposarcoma, a rare soft-tissue cancer. Participants took either brigimadlin pills or doxorubicin infusions every 3 weeks. The main goal was to…

This study looked at the safety and effectiveness of the drug JARDIANCE® when taken daily for a long time by people with chronic heart failure in Japan. About 1,200 patients who had never taken this drug before were followed to track side effects, deaths, and hospital visits. The…

This early-phase study tested a new oral drug, BI 1015550, in 15 people with idiopathic pulmonary fibrosis (IPF) who were not taking other treatments. The main goal was to check safety and side effects, and to measure how the drug moves through the body. The study is complete, bu…

This study tested a medicine called spesolimab in 27 adults with Crohn's disease who also have fistulas near the anus. The goal was to see if the drug helps close these fistulas better than a placebo. Participants received either the drug or a placebo by IV every 4 weeks for 24 w…

This study looked at the long-term safety and effectiveness of spesolimab for adults with hidradenitis suppurativa (HS), a painful skin condition. Participants who completed a prior spesolimab trial received injections every two weeks for two years. The main goal was to track sid…

This study checked the safety of the drug Ofev in 425 people in Japan with a type of progressive lung scarring called PF-ILD. The main goal was to see how often side effects, especially liver problems, happened in everyday use. The study did not test if the drug worked, only how …

This study followed 52 Japanese patients with generalized pustular psoriasis (GPP) who received spesolimab for the first time. Researchers monitored side effects and how the disease behaved in everyday medical practice. The goal was to see how safe the drug is and how well it con…

This study tested a new oral drug, afatinib, against a standard intravenous drug, methotrexate, in 340 adults with advanced head and neck cancer that had returned or spread and no longer responded to platinum-based chemotherapy. The main goal was to see if afatinib could delay ca…

This study tested a medicine called BI 1015550 in 1177 adults with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. Participants took either the study drug or a placebo twice daily for at least a year. The main goal was to see if th…

This early-phase trial tested a new drug called BI 754091 in 110 adults with advanced solid tumours that could not be removed by surgery or had spread. The main goal was to find a safe dose and check for side effects. Researchers also looked for signs that the drug might shrink t…

This study tested a medicine called survodutide in 218 adults with overweight or obesity and a liver condition called NASH (fatty liver with inflammation). Participants received weekly injections of survodutide or a placebo for about a year, along with diet and exercise advice. T…

This study tested a new medicine called BI 655130 in 59 adults with palmoplantar pustulosis (PPP), a skin condition causing painful pus-filled blisters on the palms and soles. The goal was to see if the drug safely reduces the severity of the pustules and plaques compared to a pl…

This study tested three doses of an experimental medicine called BI 1819479 in 322 adults with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Participants took the medicine or a placebo daily for 6 to 12 months. The main goal was to see if the drug could slow the d…

This study tested a new oral drug, BI 3706674, in 47 adults with advanced stomach, esophageal, or gastroesophageal junction cancer that had not responded to prior treatments. The goal was to find a safe dose and see if the drug could shrink tumors by blocking growth signals. The …

This study tested an experimental oral medicine called Avenciguat (BI 685509) in 214 adults with progressive systemic sclerosis (scleroderma), a disease that causes skin thickening and can damage the lungs. Participants took either the drug or a placebo three times daily for at l…

This study looked at the long-term safety of a medicine called nintedanib in children and teenagers (ages 6-17) with a lung condition that causes scarring (fibrosing interstitial lung disease). All participants took nintedanib capsules twice a day for at least 1.5 to 3 years. The…

This study tested a medicine called spesolimab to see if it can prevent flare-ups in people with generalized pustular psoriasis (GPP), a rare and serious skin condition. 123 people aged 12 to 75 with clear or nearly clear skin joined the study. They received either one of three d…

This study tested a new medicine called BI 655130 in 51 adults with moderate to severe atopic dermatitis (eczema). The goal was to see if it is safe and can reduce skin symptoms like redness, itching, and thickening compared to a placebo. Participants received the drug or a dummy…

This study tested a daily medicine called iclepertin to see if it improves memory and thinking in adults with schizophrenia. About 620 participants took either iclepertin or a placebo for 26 weeks, while continuing their usual schizophrenia medications. Researchers measured chang…

This study tested a medicine called spesolimab in 52 adults with moderate to severe hidradenitis suppurativa, a chronic skin disease causing painful lumps and boils. Participants received either spesolimab or a placebo (dummy treatment) for about 3 months. Doctors counted skin le…

This study tested whether a daily medicine called iclepertin can improve learning and memory in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo for 26 weeks while continuing their usual schizophrenia treatment. Researchers measured thinking sk…

This study looked at how healthy men absorb, break down, and eliminate a new drug called BI 1015550. Six participants took a single dose with a radioactive label so scientists could track it in urine and stool. The goal was to understand how the drug leaves the body and to check …

This completed study looked at over 10,000 people in France who were prescribed antifibrotic drugs for idiopathic pulmonary fibrosis. Researchers wanted to see how many patients continued their treatment for up to 30 months and what factors might cause them to stop. The goal is t…

This study looked at how taking multiple doses of itraconazole changes the way a single dose of BI 3031185 moves through the body. It involved 14 healthy men aged 18 to 55. The goal was to measure drug levels in the blood, not to treat any disease.

This early-stage study looked at how multiple doses of an experimental drug (BI 425809) affect the way the body processes midazolam, a sedative used in medical procedures. Fifteen healthy men took part to see if the drug changes how fast midazolam is broken down. The goal was to …

This study looked at how a new medicine called BI 456906 (for obesity and liver disease) behaves in the blood of people with and without kidney problems. 42 adults received a single injection and were divided into groups based on kidney function. The goal was to see if kidney pro…

This early-stage study tested a new drug called BI 425809 in 25 healthy men to see how much of it reaches the brain. Researchers measured drug levels in blood and spinal fluid after multiple doses. The goal was to understand the drug's safety and how it behaves in the body, not t…

This study looked at how a new drug called BI 425809 changes the way the body processes four common medications (midazolam, warfarin, omeprazole, and digoxin) in 13 healthy men. The goal was to see if BI 425809 affects how these drugs are broken down, which helps doctors understa…

This early-stage study looked at how a new drug called BI 655130 enters the bloodstream when given as a shot under the skin compared to through an IV. Thirty-six healthy adults took part. The goal was not to treat any disease, but to understand the drug's safety and how the body …

This study tested whether two different pill versions of the experimental drug nerandomilast are absorbed the same way in the body. Sixty-four healthy adults aged 18 to 50 took a single dose of each version on separate days. The goal was to check if the new version works like the…

This study tested three different versions (formulations) of an experimental drug called BI 456906 in 30 healthy adults. The goal was to see how well each version is absorbed into the body. Participants received a single dose of each version in random order, and blood samples wer…

This study looked at whether taking itraconazole changes how much of another drug, BI 764198, stays in the blood. Fourteen healthy men took BI 764198 alone and then with itraconazole. The results help doctors understand how to safely combine these medicines.

This early-stage study tested a new drug called BI 3006337 in 36 healthy Japanese men to see if it is safe and how the body handles it. Participants received either the drug or a placebo as a single shot or weekly shots for 6 weeks. The goal was to gather safety information, not …

This study checked if two different versions of the drug nerandomilast are absorbed the same way in the body. Sixty-four healthy adults each took a single dose of both formulations on separate days. The goal was to confirm the new formulation works just like the one used in later…

This study looked at how a new cancer drug, zongertinib, changes the way other common drugs (dabigatran, rosuvastatin, metformin, and furosemide) are processed in the body. Thirty-two healthy men took zongertinib along with these other drugs, and researchers measured drug levels …

This study looked at how different levels of kidney function affect the way the body processes iclepertin, a medicine being developed for brain diseases. 36 adults with and without kidney problems took a single tablet of iclepertin. Researchers measured the drug levels in their b…

This study looked at how taking multiple doses of itraconazole, a common antifungal, changes the way the body handles a single dose of zongertinib, an experimental cancer drug. Sixteen healthy men participated to measure drug levels in the blood. The goal was to understand potent…

This early-stage study tested a new drug called BI 3034701 in 125 healthy men and people with overweight or obesity. The main goal was to see if different doses are safe and how the drug enters the blood. Participants received either the drug or a placebo as an injection under th…

This study looked at how taking multiple doses of carbamazepine changes the way the body absorbs a single dose of nerandomilast. Sixteen healthy men aged 18 to 55 took part. The goal was to measure drug levels in the blood, not to treat any disease.

This study involved 32 healthy adults to see how two different versions of a vicadrostat/empagliflozin combination are absorbed by the body. It also looked at whether taking the drug with food changes its absorption. Participants took a single dose of each version, and their bloo…

This early-stage study looked at how taking the drug BI 1015550 with or without food changes its levels in the blood. Twelve healthy men aged 18 to 55 took part. The goal was simply to measure the drug's absorption, not to treat any disease.

This study looked at how the drug BI 1291583 is broken down and removed from the body. Eight healthy men took a single dose with a radioactive label, and researchers measured the drug and its byproducts in their blood, urine, and stool over several weeks. The goal was to understa…

This study tested how well a new drug, BI 1015550, is absorbed by the body when taken in different pill forms and with or without food. Twenty-four healthy adults each took the drug three times under different conditions. The goal was to find the best pill form and understand if …

This study looked at how a new medicine, BI 655130, affects the body in 8 adults with moderate to severe ulcerative colitis. The main goal was to understand the drug's mechanism by measuring changes in gene activity in the gut lining. Researchers also checked for safety and signs…

This study looked at how a new drug called BI 764198 changes the amount of metformin in the blood when both are taken together. Fourteen healthy adults took metformin alone and then with BI 764198 to compare the levels. The goal was to gather safety and dosing information, not to…

This study looked at how taking multiple doses of an experimental drug called BI 1015550 changes the way the body processes midazolam, a sedative. Fifteen healthy men aged 18 to 55 took part. The goal was to see if BI 1015550 speeds up or slows down the breakdown of midazolam, wh…

This study looked at over 1,300 people with rheumatoid arthritis who have a higher risk of developing interstitial lung disease (ILD). The goal was to create a simple tool using common risk factors like age, smoking history, and certain blood tests to decide who should get a CT s…

This study looked at how taking bosentan (a drug that affects liver enzymes) changes the amount of another drug, BI 425809, in the blood. Fourteen healthy men took BI 425809 alone and then with bosentan. The goal was to see if bosentan reduces the levels of BI 425809, which could…

This study looked at how a new drug, BI 655130, enters the body when injected in different ways. 48 healthy adults received the drug either as two belly injections or one belly or thigh injection. The goal was to measure drug levels in the blood, not to treat any disease.

This study checked whether zongertinib tablets made by two different manufacturers are absorbed the same way in the body. Fifty-six healthy adults took a single dose of each version at different times. The goal was to see if the two versions are bioequivalent, meaning they work t…

This study looked at how the experimental brain drug iclepertin is processed in people with mild to moderate liver problems compared to those with healthy livers. 29 adults took a single tablet, and researchers measured drug levels in the blood. The goal was to see if liver impai…

This study looked at how the body handles five common drugs (caffeine, warfarin, omeprazole, metoprolol, and midazolam) in healthy adults and in people with mild or moderate liver cirrhosis. Researchers measured drug levels in the blood to see if liver scarring changes how these …

This early-stage study looked at how a single dose of the experimental drug BI 1015550 is processed in the body when taken with or without the antifungal medicine itraconazole. Sixteen healthy men participated to help researchers understand if itraconazole changes the levels of B…

This study looked at how the antibiotic rifampicin changes the way the body handles a single dose of BI 425809, an experimental drug for cognitive problems. Sixteen healthy men took BI 425809 alone and then again after several days of rifampicin. The goal was to measure drug leve…

This study looked at two different versions of the drug nerandomilast in 15 healthy adults. The goal was to see how the body processes each version and whether taking the new version with food changes its absorption. Participants took single doses of each version, and researchers…

This early-stage study tested a new drug called BI 706321 in 73 healthy men to see if it is safe and how the body processes it. Participants received single rising doses of the drug or a placebo. The goal was to gather safety information and measure drug levels in the blood, not …

This early-stage trial tested a single dose of BI 1015550 in 24 healthy Chinese adults to see how the drug is processed by the body and whether it is safe. Participants were monitored for side effects and drug levels in the blood. Since this is a Phase 1 study in healthy people, …

This study looked at how taking the antibiotic erythromycin changes the amount of a new drug, BI 1291583, in the blood. Twenty healthy adults took both drugs in a fixed order. The goal was to see if the antibiotic affects how the body processes the new drug, which helps guide fut…

This study looked at how taking multiple doses of zongertinib changes the way the body processes three other drugs: midazolam, omeprazole, and repaglinide. Sixteen healthy men took these drugs alone and then again while on zongertinib. The goal was to see if zongertinib affects t…

This study tested whether taking the experimental drug Zongertinib with or without food changes how much of it gets into the blood. Sixteen healthy men each took one dose under both conditions. The results will help doctors decide the best way to give the drug in future trials.

This study followed 158 adults with chronic fibrosing interstitial lung disease (a type of progressive lung scarring) who were starting the medication nintedanib. Researchers wanted to see if changes in lung function (measured by how much air a person can forcefully exhale) over …

This early-stage study looked at how much of the experimental drug BI 425809 gets into the bloodstream when taken as a pill compared to a tiny intravenous dose. Six healthy men participated to help researchers understand the drug's absorption and processing. The results will guid…

This completed Phase 1 trial studied how the experimental drug BI 1015550 is absorbed when taken as a tablet. Eight healthy men received both an oral tablet and a tiny intravenous radioactive tracer dose. The goal was to measure the drug's bioavailability — how much reaches the b…

This study looked at whether a new weight-loss injection (BI 456906) changes how the body processes three common drugs: bupropion (an antidepressant), caffeine, and midazolam (a sedative). Thirty-four healthy adults with overweight or obesity took these drugs alone and then again…

This early-stage study tested a single dose of a new drug called BI 3006337 in 80 healthy men. The main goal was to check if the drug is safe and how the body processes it. No treatment for any disease was evaluated.

This study looked at whether taking the experimental drug BI 1015550 with food changes how the body absorbs it. 18 healthy adults took the drug once with a meal and once without, and researchers measured drug levels in their blood. The goal was to understand if food affects the d…

This study looked at whether taking a new drug (BI 425809) with food changes how the body absorbs it. Sixteen healthy adults took the drug once with a meal and once on an empty stomach. Researchers measured drug levels in the blood to see if food made a difference. The results wi…